Competitive intelligence guide
How to build a KRAS G12C clinical trial landscape quickly
A step-by-step method for a KRAS G12C competitive trial landscape from ClinicalTrials.gov, EU registries and abstracts, with a dated table of 24 active trials.
To build a KRAS G12C competitive landscape quickly, query the ClinicalTrials.gov API for "KRAS G12C" with active statuses, normalize drug code names to generic names, de-duplicate, and tag each trial by drug, sponsor, phase, line of therapy and tumor. Then check EU registries (CTIS and the EU Clinical Trials Register) and recent conference abstracts for trials and data the US registry misses. On 1 November 2026 that query returned 144 recruiting, active or not-yet-recruiting trials, 24 of them phase 3; the table below shows the most informative.
What a KRAS G12C landscape needs to show
A portfolio committee usually asks four things. Which drugs are in development? Who sponsors them? How far along is each? Which settings are crowded?
So each row needs a drug, a sponsor, a phase, a setting or line of therapy, a tumor type, a status and a link to the record. Without the link, nobody can check the row.
For KRAS G12C the settings matter as much as the drugs. Most late-stage work is in non-small cell lung cancer (NSCLC), split between previously treated, first-line and resected disease. Colorectal cancer is the second cluster.
Step 1: Pull the trials from ClinicalTrials.gov
The ClinicalTrials.gov API v2 returns structured study records in JSON. We used this query:
https://clinicaltrials.gov/api/v2/studies?query.term=KRAS%20G12C&filter.overallStatus=RECRUITING|ACTIVE_NOT_RECRUITING|NOT_YET_RECRUITING&pageSize=200&countTotal=true
- query.term searches the whole record, so it catches trials that name the mutation only in eligibility criteria.
- filter.overallStatus keeps trials that are recruiting, active but not recruiting, or not yet recruiting. Without it, the same search returned 224 trials, including completed and terminated ones.
- countTotal=true reports the total, so you know whether to page with pageToken.
Run a second pass with query.intr for each drug name and code. This finds trials that name the drug but describe the mutation differently, such as "KRAS p.G12C".
KRAS G12C trial landscape, as of 1 November 2026
The query returned 144 trials: 24 phase 3, 2 phase 2/3, and most of the rest phase 1 or 2. The table keeps the phase 3 trials of G12C-selective drugs and a few earlier trials of newer agents. Settings come from each record's official title.
| Drug and regimen | Sponsor (registry) | Phase | Setting or line | Tumor | Status | Record |
|---|---|---|---|---|---|---|
| Sotorasib + platinum doublet | Amgen | 3 | First line, PD-L1 negative | NSCLC | Recruiting | NCT05920356 (CodeBreaK 202) |
| Sotorasib + panitumumab + FOLFIRI | Amgen | 3 | First line | Colorectal | Recruiting | NCT06252649 (CodeBreaK 301) |
| Adagrasib vs docetaxel | Mirati Therapeutics | 3 | Previously treated | NSCLC | Active, not recruiting | NCT04685135 (KRYSTAL-12) |
| Adagrasib + cetuximab | Mirati Therapeutics | 3 | After first-line therapy | Colorectal | Active, not recruiting | NCT04793958 (KRYSTAL-10) |
| Adagrasib + pembrolizumab + chemo | Mirati Therapeutics | 3 | First line, non-squamous | NSCLC | Recruiting | NCT06875310 (KRYSTAL-4) |
| Divarasib vs sotorasib or adagrasib | Hoffmann-La Roche | 3 | Previously treated | NSCLC | Active, not recruiting | NCT06497556 (Krascendo 1) |
| Divarasib + pembrolizumab | Hoffmann-La Roche | 3 | First line, non-squamous | NSCLC | Recruiting | NCT06793215 (Krascendo 2) |
| Divarasib vs immunotherapy or observation | Hoffmann-La Roche | 3 | Resected stage II–III (adjuvant) | NSCLC | Recruiting | NCT07541170 (KRASCENDO 3) |
| Olomorasib + pembrolizumab ± chemo | Eli Lilly | 3 | First line | NSCLC | Recruiting | NCT06119581 (SUNRAY-01) |
| Olomorasib + immunotherapy | Eli Lilly | 3 | Resected or unresectable | NSCLC | Recruiting | NCT06890598 (SUNRAY-02) |
| Calderasib (MK-1084) + pembrolizumab | Merck Sharp & Dohme | 3 | First line, PD-L1 ≥50% | NSCLC | Recruiting | NCT06345729 (KANDLELIT-004) |
| Calderasib + cetuximab + mFOLFOX6 | Merck Sharp & Dohme | 3 | First line | Colorectal | Recruiting | NCT06997497 (KANDLELIT-012) |
| Calderasib + pembrolizumab (adjuvant) | Merck Sharp & Dohme | 3 | Resected stage IIA–IIIB | NSCLC | Recruiting | NCT07431827 (KANDLELIT-013) |
| Glecirasib (JAB-21822) + JAB-3312 | Allist Pharmaceuticals | 3 | First line, non-squamous | NSCLC | Recruiting | NCT06416410 |
| Garsorasib (D-1553) vs docetaxel | Chia Tai Tianqing | 3 | After standard therapy | NSCLC | Recruiting | NCT06300177 |
| Garsorasib (D-1553) + IN10018 | InxMed | 3 | First line, non-squamous | NSCLC | Recruiting | NCT07174908 |
| Fulzerasib (IBI351) + ivonescimab | Shanghai Chest Hospital | 2 | First line | NSCLC | Not yet recruiting | NCT06936644 |
| JDQ443 vs docetaxel | Novartis | 3 | Previously treated | NSCLC | Active, not recruiting | NCT05132075 (KontRASt-02) |
| HRS-7058 vs investigator-chosen G12C inhibitor | Shandong Suncadia | 3 | After standard therapy | NSCLC | Not yet recruiting | NCT07601048 |
| JMKX001899 vs docetaxel | Jemincare | 3 | Previously treated | NSCLC | Not yet recruiting | NCT07242274 |
| Sosimerasib + IN10018 | Shanghai Jeyou | 3 | First line, non-squamous | NSCLC | Not yet recruiting | NCT07833202 |
| HS-10370 + chemo ± adebrelimab | Jiangsu Hansoh | 3 | First line, non-squamous | NSCLC | Not yet recruiting | NCT07822542 |
| D3S-001 alone or in combination | D3 Bio (Wuxi) | 1/2 | Advanced, dose escalation and expansion | Solid tumors | Recruiting | NCT05410145 |
| Elironrasib ± daraxonrasib | Revolution Medicines | 1b/2 | Advanced | Solid tumors | Recruiting | NCT06128551 |
Not shown: phase 3 trials in which G12C is one arm among several, such as the B-FAST umbrella study (NCT03178552), and pan-RAS trials such as RASolve 301 (NCT06881784). Also not shown: further calderasib phase 3 trials (NCT07190248, NCT07554339) and many investigator-led phase 2 studies.
Registry records change often. Check each record's status before you rely on it.
Step 2: Normalize drug names and de-duplicate
The same drug appears under several names. Map every code name to one generic name before you count anything.
| Code name in records | Generic name | Where the link is stated |
|---|---|---|
| AMG 510 | Sotorasib | NCT04625647 title and interventions |
| MRTX849 | Adagrasib | NCT04685135 intervention names |
| LY3537982 | Olomorasib | NCT06119581 intervention names |
| MK-1084 | Calderasib | NCT06345729 |
| JAB-21822 | Glecirasib | NCT05009329 intervention names |
| IBI351, GFH925 | Fulzerasib | NCT05504278, NCT06936644 |
| D-1553 | Garsorasib | Phase 2 publication (D1553-102 Study Group) |
| RMC-6291 | Elironrasib | NCT06128551 intervention names |
Then de-duplicate:
- One trial can appear in several registries. Match on the sponsor protocol number and secondary IDs, not on titles.
- Drop or flag trials where KRAS G12C is a single cohort in a multi-drug or umbrella study.
- Separate G12C-selective inhibitors from pan-RAS or RAS(ON) multi-selective drugs. Both appear in a KRAS G12C search.
- Exclude observational and real-world studies unless the committee wants them.
Step 3: Check EU registries
Some trials run in Europe are not on ClinicalTrials.gov, or appear there late. Check both EU sources:
- CTIS. The Clinical Trials Information System went live with a searchable public website on 31 January 2022. Search it at euclinicaltrials.eu.
- EU Clinical Trials Register. Trials started before 31 January 2023 under the old Clinical Trials Directive are in the EU Clinical Trials Register, which uses EudraCT numbers.
Search both by drug name and code name. Record the EU trial number alongside the NCT number so the same trial is not counted twice.
For KRAS G12C, many early trials come from Chinese sponsors. Check the national registry of each sponsor's home country too.
Step 4: Add conference abstracts and publications
Registries tell you what is running. They rarely tell you how it is going. Results first appear at major oncology meetings, often months before a journal paper.
- Search abstracts from the main lung and gastrointestinal oncology meetings by drug name and code name.
- Link each abstract to its trial by NCT or EU number. Abstracts often cite the number.
- Record the data cut, the number of patients and the endpoints reported. Do not compare response rates across trials with different lines and populations.
- Search PubMed for full papers, such as the garsorasib phase 2 trial in Lancet Respiratory Medicine (2024).
How TrialMind's trial landscape workflow does this
TrialMind, from Keiji AI, has a trial landscape workflow for competitive and portfolio intelligence teams. According to the solution page:
- It pulls trials from ClinicalTrials.gov, the EU Clinical Trials Register (EudraCT) and other registries, and organizes them by phase, sponsor and status.
- It reads publications and conference abstracts directly, and links every claim to the trial record, publication or abstract it came from.
- You describe the task, review the proposed plan before anything runs, then check the result with its sources.
- The solution page shows an example KRAS G12C landscape of 166 trials across 12 drugs, built from ClinicalTrials.gov (searched October 2026). Its search scope differs from the query above, so the counts are not directly comparable.
The table on this page was built by hand from the public API, not by TrialMind.
Frequently asked questions
- How many KRAS G12C trials are active right now?
- On 1 November 2026, a ClinicalTrials.gov search for "KRAS G12C" returned 144 trials that were recruiting, active but not recruiting, or not yet recruiting. Twenty-four were phase 3. Counts change weekly, so rerun the query.
- Which KRAS G12C inhibitors are in phase 3?
- In the registry on 1 November 2026, phase 3 trials included sotorasib, adagrasib, divarasib, olomorasib, calderasib, glecirasib, garsorasib, JDQ443, HRS-7058, JMKX001899, sosimerasib and HS-10370.
- Is ClinicalTrials.gov enough for a competitive landscape?
- It is the best place to start, but not enough on its own. Check CTIS and the EU Clinical Trials Register, national registries for sponsors outside the US and EU, and recent conference abstracts for results.
- How do I avoid counting the same trial twice?
- Match trials across registries by sponsor protocol number and secondary IDs, map drug code names to generic names, and flag umbrella studies where G12C is one cohort among many.
- Can an AI tool build this landscape for me?
- Yes. Tools such as TrialMind read the registries, publications and abstracts and return a sourced landscape. Whatever tool you use, keep a link to each record so the result can be checked.
See TrialMind on your own question
A 30-minute walkthrough on a study like yours, with sources and code you can check.
Sources · checked 2026-11-01
Product details come from each company’s public pages. Spotted something out of date? Tell us and we will correct it.
- ClinicalTrials.gov API v2 documentation
- EMA: Clinical Trials Information System (CTIS)
- CTIS public search
- EU Clinical Trials Register
- Li et al. Garsorasib in KRAS G12C NSCLC, Lancet Respir Med 2024
- TrialMind for Competitive & Portfolio Intelligence
- NCT05920356: Sotorasib + platinum doublet
- NCT06252649: Sotorasib + panitumumab + FOLFIRI
- NCT04685135: Adagrasib vs docetaxel
- NCT04793958: Adagrasib + cetuximab
- NCT06875310: Adagrasib + pembrolizumab + chemo
- NCT06497556: Divarasib vs sotorasib or adagrasib
- NCT06793215: Divarasib + pembrolizumab
- NCT07541170: Divarasib vs immunotherapy or observation
- NCT06119581: Olomorasib + pembrolizumab ± chemo
- NCT06890598: Olomorasib + immunotherapy
- NCT06345729: Calderasib (MK-1084) + pembrolizumab
- NCT06997497: Calderasib + cetuximab + mFOLFOX6
- NCT07431827: Calderasib + pembrolizumab (adjuvant)
- NCT06416410: Glecirasib (JAB-21822) + JAB-3312
- NCT06300177: Garsorasib (D-1553) vs docetaxel
- NCT07174908: Garsorasib (D-1553) + IN10018
- NCT06936644: Fulzerasib (IBI351) + ivonescimab
- NCT05132075: JDQ443 vs docetaxel
- NCT07601048: HRS-7058 vs investigator-chosen G12C inhibitor
- NCT07242274: JMKX001899 vs docetaxel
- NCT07833202: Sosimerasib + IN10018
- NCT07822542: HS-10370 + chemo ± adebrelimab
- NCT05410145: D3S-001 alone or in combination
- NCT06128551: Elironrasib ± daraxonrasib